Discover open access scientific publications

Search, annotate, share and cite publications

Publications by L. Sequeira

Financial and Clinical Implications of Intramuscular Versus Subcutaneous Interferon Beta-1a in Portugal, Based on the Findings From the Cochrane Collaboration Review of First-Line Treatments for Relapsing-Remitting Multiple Sclerosis

Value in Health

English

Related publications

A Budget Impact Analysis of the Cochrane Collaboration Review of First-Line Treatments for Relapsing-Remittimg Multiple Sclerosis

English

Cost-Effectiveness of Glatiramer Acetate and Interferon Beta-1a for Relapsing-Remitting Multiple Sclerosis, Based on the Combirx Study

English

Cost-Utility Analyses of Natalizumab Versus Interferon Beta-1a 44 MCG for Rapidly Evolving Severe Relapsing-Remitting Multiple Sclerosis (RESRRMS) Patients in Brazil

English

Pregnancy Outcomes in Multiple Sclerosis Following Subcutaneous Interferon Beta-1a Therapy

Multiple Sclerosis

Neurology

2011

English

Pnd27 - Cost Implications in the Selection of First Line Treatment for Highly Active Relapsing Multiple Sclerosis in Portugal

English

An Economic Evaluation of Subcutaneous and Intramuscular Interferon Beta-1a in Multiple Sclerosis Using a Direct Head-To-Head Study

English

Pnd34 - Payer and Societal Benefit of Peginterferon Beta-1a Versus Glatiramer Acetate in Patients With Relapsing-Remitting Multiple Sclerosis in Spain

English

Pnd33 - Payer and Societal Benefit of Peginterferon Beta-1a Versus Glatiramer Acetate in Patients With Relapsing-Remitting Multiple Sclerosis in Italy

English

Pnd120 - Treatment Decisions About First-Line Disease-Modifying Treatments (Dmts) in Relapsing Remitting Multiple Sclerosis: A Systematic Review of Patient Needs and Preferences

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by L. Sequeira

Financial and Clinical Implications of Intramuscular Versus Subcutaneous Interferon Beta-1a in Portugal, Based on the Findings From the Cochrane Collaboration Review of First-Line Treatments for Relapsing-Remitting Multiple Sclerosis

Related publications

A Budget Impact Analysis of the Cochrane Collaboration Review of First-Line Treatments for Relapsing-Remittimg Multiple Sclerosis

Cost-Effectiveness of Glatiramer Acetate and Interferon Beta-1a for Relapsing-Remitting Multiple Sclerosis, Based on the Combirx Study

Cost-Utility Analyses of Natalizumab Versus Interferon Beta-1a 44 MCG for Rapidly Evolving Severe Relapsing-Remitting Multiple Sclerosis (RESRRMS) Patients in Brazil

Pregnancy Outcomes in Multiple Sclerosis Following Subcutaneous Interferon Beta-1a Therapy

Pnd27 - Cost Implications in the Selection of First Line Treatment for Highly Active Relapsing Multiple Sclerosis in Portugal

An Economic Evaluation of Subcutaneous and Intramuscular Interferon Beta-1a in Multiple Sclerosis Using a Direct Head-To-Head Study

Pnd34 - Payer and Societal Benefit of Peginterferon Beta-1a Versus Glatiramer Acetate in Patients With Relapsing-Remitting Multiple Sclerosis in Spain

Pnd33 - Payer and Societal Benefit of Peginterferon Beta-1a Versus Glatiramer Acetate in Patients With Relapsing-Remitting Multiple Sclerosis in Italy

Pnd120 - Treatment Decisions About First-Line Disease-Modifying Treatments (Dmts) in Relapsing Remitting Multiple Sclerosis: A Systematic Review of Patient Needs and Preferences